Effect of Curcumin and Vitamin D in patients with Non-alcoholic fatty liver disease

The Combined Effect of Cholecalciferol and Curcumin on metabolic parameters, oxidative stress biomarkers and inflammation in patients with Non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170430033730N7

Enrollment

Registered

2021-02-24

Start date

2021-02-13

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: One sub-gels containing (80 mg curcumin + 400 IUD3) will receive daily for 8 weeks. Intervention 2: Control group: One sub-gels of placebo will receive daily f

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with Non-alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Patients who do not want to cooperate People who smoke People who drink alcohol Patients with gastrointestinal disorders Diabetic Patients Patients with inflammatory conditions such as allergies and autoimmune diseases

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;AST. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.	—

Secondary

Measure	Time frame
Lipid profiles. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;FBS. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;Insulin. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;Glutathione. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;MDA. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;TNF-a. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;IL-8. Timepoint: Beginning and end of the study. Method of measurement: ELISA.	—

Measure

Time frame

Lipid profiles. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;FBS. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;Insulin. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;Glutathione. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;MDA. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;TNF-a. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;IL-8. Timepoint: Beginning and end of the study. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mehdi Mirhashemi

Qazvin University of Medical Sciences

mirhashemism@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026